<PAGE>   1
                                    FORM 10-Q

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549


    [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
        EXCHANGE ACT OF 1934

                  For the quarterly period ended June 30, 1997

                                              OR

          [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

          For the transition period from _____________ to _____________

                          Commission file number 1-9983


                            OEC MEDICAL SYSTEMS, INC.
                                  (Registrant)


                      Incorporated in the State of Delaware

                I.R.S. Employer Identification Number 94-2538512


              384 Wright Brothers Drive, Salt Lake City, Utah 84116
                    (Address of Principal Executive Offices)


                            Telephone: (801) 328-9300


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such requirements
for the past 90 days.

                              Yes [X]     No[ ]

As of July 31, 1997, there were 13,344,787 shares of Common Stock ($.01 par
value) outstanding.


<PAGE>   2
PART I. Financial Information
ITEM 1. Financial Statements


                            OEC MEDICAL SYSTEMS, INC.
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (unaudited)
              FOR THE QUARTER & SIX MONTHS ENDED JUNE 30, 1997 AND
                  1996 (In thousands, except per share amounts)


<TABLE>
<CAPTION>
                                         Quarter Ended June 30,     Six Months Ended June 30,

                                           1997          1996          1997          1996
                                         --------      --------      --------      --------
<S>                                      <C>           <C>           <C>           <C>     

Net sales
  Product                                $ 34,570      $ 26,465      $ 62,690      $ 48,663
  Service                                   4,310         4,129         8,504         8,114
                                         --------      --------      --------      --------
     Total net sales                       38,880        30,594        71,194        56,777
                                         --------      --------      --------      --------
Cost of sales
  Product                                  19,783        15,491        36,417        28,693
  Service                                   3,134         2,858         6,117         5,301
                                         --------      --------      --------      --------
     Total cost of sales                   22,917        18,349        42,534        33,994
                                         --------      --------      --------      --------
     Gross margin                          15,963        12,245        28,660        22,783
                                         --------      --------      --------      --------

Operating Expenses
  Research and development                  2,894         2,113         5,519         4,218
  Marketing and sales                       6,621         5,265        11,904         9,780
  Administrative, general and other         2,315         1,729         3,978         3,094
                                         --------      --------      --------      --------
     Total operating expenses              11,830         9,107        21,401        17,092
                                         --------      --------      --------      --------

Operating income                            4,133         3,138         7,259         5,691

Interest income                               202           199           457           387
Interest expense                               (2)           (1)           (5)           (3)
                                         --------      --------      --------      --------

Income before income taxes                  4,333         3,336         7,711         6,075

Income tax expense                          1,590          --           2,667          --
                                         --------      --------      --------      --------
Net income                               $  2,743      $  3,336      $  5,044      $  6,075
                                         ========      ========      ========      ========
Net income  per common and
  common equivalent share:               $   0.21      $   0.26      $   0.39      $   0.48
                                         ========      ========      ========      ========

Common and
  common equivalent shares                 13,082        12,795        13,077        12,783
</TABLE>


                                     (more)

                                                                               2
<PAGE>   3
                            OEC MEDICAL SYSTEMS, INC.
                           CONSOLIDATED BALANCE SHEETS
                       JUNE 30, 1997 AND DECEMBER 31, 1996
                                 (In thousands)

<TABLE>
<CAPTION>
                                     ASSETS
                                                                   1997           1996
                                                                ---------      ---------
<S>                                                            <C>             <C>      
                                                               (Unaudited)
Current Assets:
   Cash and temporary cash investments                          $  14,235      $  17,103
   Accounts and notes receivable, net of
     allowances of $1,063 and $853, respectively                   36,390         33,191
   Inventories                                                     26,589         23,868
   Prepaid expenses and other current assets                        2,298          1,451
   Deferred income taxes                                            8,510          8,006
                                                                ---------      ---------
      Total current assets                                         88,022         83,619
Long-term receivables                                               1,163          1,627
Property and equipment, net                                        12,588         11,903
Cost in excess of net assets acquired, net of accumulated
   amortization of $8,669 and $8,183, respectively                 11,379         10,213
Deferred income taxes                                               2,399          3,879
Other assets, net                                                     729            705
                                                                ---------      ---------
                                                                $ 116,280      $ 111,946
                                                                =========      =========

                      LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:
   Accounts payable                                             $   8,746      $   7,358
   Accrued salaries and benefits                                    3,071          4,127
   Accrued warranty and installation costs                          1,957          1,748
   Deferred income and customer deposits                            5,648          5,462
   Income taxes payable                                               211            509
   Accrued  legal fees and litigation settlements                   4,180          4,062
   Accrued distributor commissions                                  2,902          2,891
   Other accrued liabilities                                        3,747          3,615
                                                                ---------      ---------
      Total current liabilities                                    30,462         29,772
                                                                ---------      ---------

Stockholders' equity:
   Preferred stock, $.01 par value
      Authorized--2,000 shares, including 1,100 shares
      of convertible preferred stock, none outstanding
   Common stock, $.01 par value
      Authorized--30,000 shares
      Outstanding--13,311 and 13,158 shares, respectively             133            132
   Capital in excess of par value                                  80,321         79,341
   Retained earnings                                               14,830          9,786
   Treasury stock, 942 and 801 shares at cost, respectively        (9,090)        (6,850)
   Foreign currency translation adjustment                           (376)          (235)
                                                                ---------      ---------
      Total stockholders' equity                                   85,818         82,174
                                                                ---------      ---------
                                                                $ 116,280      $ 111,946
                                                                =========      =========
</TABLE>
                                      # # #


                                                                               3
<PAGE>   4
                            OEC MEDICAL SYSTEMS, INC.
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                 FOR THE SIX MONTHS ENDED JUNE 30, 1997 AND 1996
                                 (In thousands)
                                   (unaudited)

<TABLE>
<CAPTION>
                                                                                              1997          1996
                                                                                            --------      --------
<S>                                                                                         <C>           <C>     
OPERATING ACTIVITIES:
   Net income                                                                               $  5,044      $  6,075
   Adjustments to reconcile net income
      to net cash provided (used) by operating activities:
      Depreciation and amortization                                                            1,667         1,420
      Bad debt expense                                                                          (240)          (45)
      Deferred income tax expense (benefit)                                                      976          (887)
      Current tax benefit attributable to stock options exercised                                486          --
      Changes in current assets and liabilities, net of effects
         of purchase of subsidiary:
           Accounts and notes receivable, net                                                 (2,817)       (6,206)
           Inventories                                                                        (1,996)       (3,446)
           Prepaid expenses and other current assets                                            (765)         (492)
           Other assets, net                                                                    (213)         (171)
           Accounts payable                                                                      364         1,966
           Accrued salaries and benefits                                                      (1,056)         (134)
           Accrued warranty and installation costs                                               209             9
           Deferred income and customer deposits                                                 186           377
           Income taxes payable                                                                 (298)         (154)
           Accrued legal fees and litigation settlements                                         118             1
           Accrued distributor commissions                                                        11           487
           Other accrued liabilities                                                            (397)          938
                                                                                            --------      --------
      Net cash provided (used) by operating activities                                         1,279          (262)

INVESTING ACTIVITIES:
   Increase in long-term receivables                                                            (634)         (571) 
   Additions to property and equipment                                                        (1,744)       (2,248)
   Net cash acquired upon purchase of subsidiary                                                 116          --
   Other                                                                                        (141)         (162)
                                                                                            --------      --------
      Net cash used by investing activities                                                   (2,403)       (2,918)

FINANCING ACTIVITIES:
   Common stock issued under benefit plans                                                     1,496           578
   Repurchase of warrants                                                                     (1,000)         --
   Purchases of treasury stock                                                                (2,240)       (1,319)
                                                                                            --------      --------
   Net cash used by financing activities                                                      (1,744)         (741)

   Net decrease in cash and short-term cash investments                                       (2,868)       (3,984)
   Cash and short-term cash investments at beginning of period                                17,103        16,584
                                                                                            --------      --------

   Cash and short-term cash investments at end of period                                    $ 14,235      $ 12,600

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
   Cash paid during the period for interest                                                 $      5      $      3
   Cash paid during the period for income taxes                                             $  1,503      $    403
SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND FINANCING  ACTIVITIES:
During the six months ended June 30, 1997, the Company increased its ownership
in BMS from 19.8% to 100% as follows:
                             Original 19.8% interest $ 190 January 1, 1997
                             transactions:
                               Cash payment                                                      193
                               Options granted                                                   274
                               Loans converted to equity                                         615
                                                                                            --------
                                 Total investment                                              1,272
                               Net Liabilities acquired                                          380
                                                                                            --------      
                             Total purchase price in excess of net liabilities acquired     $  1,652
                                                                                            ========      
</TABLE>


                            (See Accompanying Notes)


                                                                               4
<PAGE>   5
                            OEC MEDICAL SYSTEMS, INC.
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                             JUNE 30, 1997 AND 1996
                                   (unaudited)

1.  Interim information is unaudited but, in the opinion of Company management,
    all adjustments necessary for a fair presentation of interim results have
    been included. The results for the three and six months ended June 30, 1997
    and 1996, are not necessarily indicative of the results to be expected for
    the entire year. These consolidated financial statements and notes should be
    read in conjunction with the Company's consolidated financial statements for
    the year ended December 31, 1996, filed on Form 10-K on March 27, 1997.

2.  Inventories are stated at the lower of cost, utilizing the first-in/
    first-out method, or market. Inventories consist of the following:

<TABLE>
<CAPTION>
                                                      June 30,    December 31,
                                                        1997          1996*
                                                      --------      --------
<S>                                                   <C>           <C>     
                                                          (In thousands)
Purchased parts and
   completed subassemblies                            $ 12,391      $ 10,432
Work-in-process                                          3,322         3,097
Finished goods                                           1,425         2,023
Demonstration equipment                                 10,210         8,203
Service and repair parts                                 4,419         4,475
                                                      --------      --------

Total                                                 $ 31,767      $ 28,230
Less:  reserves for excess and obsolete inventory       (5,178)       (4,362)
                                                      --------      --------
Net                                                    $26,589       $23,868
</TABLE>

    *   Certain prior year amounts have been reclassified to conform with the
        current year's presentation.

3.  In February 1997, the Financial Accounting Standards Board issued SFAS No.
    128, "Earnings per Share." This standard establishes standards for computing
    and presenting earnings per share (EPS). SFAS No. 128 simplifies the
    approach for computing earnings per share previously found in Accounting
    Principles Board Opinion (APB) Opinion No. 5. It replaces the presentation
    of primary EPS with a presentation of basic EPS. It also requires dual
    presentation of basic and diluted EPS on the face of the income statement
    for all entries with complex capital structures.

    Under the new statement, basic EPS excludes dilution and is computed by
    dividing income available to common stockholders by the weighted-average
    number of common shares outstanding for the period. Diluted EPS reflects the
    potential dilution that could occur if securities or other contracts to
    issue common stock were exercised or converted into common stock. Diluted
    EPS is computed similarly to fully diluted EPS pursuant to APB Opinion
    No. 15.

    SFAS No. 128 is effective for financial statements issued for periods ending
    after December 15, 1997, with earlier application not permitted. The
    computation of basic EPS under SFAS No. 128 would have resulted in net
    income per common share of $0.41 for the six months ended June 30, 1997,
    compared to $0.50 for the same period in 1996. Diluted EPS computed under
    SFAS No. 128 would have resulted in net income per common share of $0.39 for
    the six months ended June 30, 1997.


                                                                               5
<PAGE>   6
                            OEC MEDICAL SYSTEMS, INC.
                 ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF
                  FINANCIAL CONDITION AND RESULTS OF OPERATIONS


Except for historical information, this discussion contains forward looking
statements that involve risks and uncertainties that could cause actual results
to differ materially from those projected. Such risk and uncertainties include
those described in the "Risk Factors" section on page 8 of this Form 10-Q.

Results of Operations

For the second quarter and six months ended June 30, 1997, OEC Medical Systems,
Inc. had net income of $2.7 million and $5.0 million, respectively, compared
with net income of $3.3 million and $6.1 million, respectively, for the same
periods last year. The results for the six month period ended June 30, 1997
reflect tax expense of $2.7 million, as compared to the same period in 1996, in
which the Company had no tax expense. Operating income improved for the second
quarter and six months ended June 30, 1997, from $3.1 million and $5.7 million,
respectively, in 1996 to $4.1 million and $7.3 million, respectively, in 1997.

The following table sets forth OEC's operating results as a percent of net
sales:

<TABLE>
<CAPTION>
                                             Three Months             Six Months
                                           1997        1996        1997        1996
                                          ------      ------      ------      ------ 
<S>                                       <C>         <C>         <C>         <C>   
 Net sales
 Product                                   88.91%      86.50%      88.06%      85.71%
 Service                                   11.09%      13.50%      11.94%      14.29%
                                          ------      ------      ------      ------ 
 Total net sales                          100.00%     100.00%     100.00%     100.00%

 Cost of sales
 Product                                   50.88%      50.63%      51.15%      50.54%
 Service                                    8.06%       9.34%       8.59%       9.34%
                                          ------      ------      ------      ------ 
 Total cost of sales                       58.94%      59.97%      59.74%      59.88%
 Gross margin                              41.06%      40.03%      40.26%      40.12%

 Operating expenses:
 Research and development                   7.44%       6.91%       7.75%       7.43%
 Marketing and sales                       17.03%      17.21%      16.72%      17.23%
 Administrative, general and other          5.95%       5.65%       5.59%       5.45%
                                          ------      ------      ------      ------ 
 Total operating expenses                  30.42%      29.77%      30.06%      30.11%
                                          ------      ------      ------      ------ 

Operating income                           10.64%      10.26%      10.20%      10.01%

Net income                                  7.06%      10.90%       7.08%      10.70%
</TABLE>


Sales and Markets

Net product sales for the quarter and six months ended June 30, 1997, were $34.6
million and $62.7 million, respectively, compared to net product sales of $26.5
million and $48.7 million for the comparable periods of 1996. This reflects a
31% and 29% increase, respectively.

The order rate for the company's core product, the Series 9600 Digital Mobile
Imaging System, is ahead of last year, both domestically and internationally.
The increase is a result of increased sales coverage and market acceptance of


                                                                               6
<PAGE>   7
the product in all regions along with growth in sales of the Series 9600 12"
image intensifier option. This system offers a wider field-of-view needed for
some existing procedures as well as new applications such as aortic stent graph
placement. Sales of the Uroview 2600 were basically flat this quarter over the
same period last year, but bookings as compared to the prior year quarter were
up significantly. Revenue from the newly introduced MINI 6600 and COMPACT 7600
C-arms contributed to the overall revenue growth as compared to the same period
last year. The 6600 is gaining market share in line with the company's
expectations, and the 7600 market acceptance has improved but, is still slightly
below company expectations. Although product sales have been improving,
continued competitive pricing pressures worldwide in all product categories are
expected to remain for the foreseeable future.

Service revenue for the quarter and six months ended June 30, 1997 was $4.3
million and $8.5 million, respectively, compared to service revenue of $4.1
million and $8.1 million for the comparable periods of 1996. Revenue growth in
service has slowed somewhat from prior years. The main reason is that
independent service organizations and the consolidation of hospitals have taken
away some of the service revenue opportunities.

Margin Analysis

OEC's gross margin expressed as a percentage of net sales increased 1.04% for
the second quarter and .13% for the six months when compared with the same
periods in 1996. Ongoing improvements in manufacturing efficiency along with the
product mix towards higher revenue type systems are the main reasons for the
increase.

Service expenses for the quarter and six months were up against last year by
$0.3 million and $.8 million, respectively. These increases are attributed to
higher labor costs, due to having to add personnel to handle the increase in
system installations as a result of increased sales and lower warranty
utilization due to increasing system reliability.

Operating Expenses

Research and development costs are up $0.8 million and $1.3 million, for the
three and six month periods, respectively, as compared to the prior year. This
reflects the Company's continuing investment in product development and
improvements such as the recently introduced Series 9600 Cardiac system and the
MINI 6600 6\4 system.

Marketing and sales expenses are up $1.4 million and $2.1 million, respectively,
for the three and six month periods compared to the prior year. This increase is
due primarily to greater commissions because of higher sales and increased costs
associated with additional sales coverage, both domestically and
internationally, to obtain the higher revenue. The Company recorded expense of
$0.4 million due to unrealized currency translation losses in the first quarter.
Expressed as a percentage of total revenue, the marketing and sales expense was
down 0.18% and .51%, respectively .

Administrative expenses are up $0.6 million and $.9 million, respectively, for
the three and six months compared to the prior year. The main reason for the
increase in the second quarter was the cost associated with the implementation
of a new computer system and associated training costs. The computer system went
live on July 1, 1997. These costs are expected to continue into the third
quarter of 1997 but at a lower level. Also there was some extra relocation
expense related to some new hires that are not expected to continue.

Income Taxes

During the second quarter and six months ended June 30, 1997, the Company
recorded $1.6 million and $2.7 million of tax expense, compared to no tax
expense in the second quarter and six months ended June 30, 1996. The reversal
of the valuation allowance for deferred tax assets in 1996 had offset the tax
provisions required for federal and state income taxes. During 1996, the company
has reversed the remaining balance of the valuation allowance for the deferred
tax assets. The company believes that it will generate enough taxable income to
fully utilize the deferred tax assets, primarily made up of tax credits, prior
to their expiration.


                                                                               7
<PAGE>   8
Liquidity and Capital Resources

Cash provided by operations for the first six months of 1997 was $1.3 million,
compared to cash used of $0.3 million for the first six months of 1996. The 1997
net income was offset by use of operating cash for higher accounts receivable
and inventory increases to support additional production due to the broadened
product line and to provide more demonstration units.

A stock repurchase program covering 750,000 shares of the Company's outstanding
common stock was announced December 1994 and the authorized amount was increased
to 1,250,000 shares in January 1996. As of June 30, 1997, 1,030,083 shares have
been repurchased at a cost of $9,606,320 of which 87,983 were retired and
942,100 shares were recorded as treasury stock. Also, $1.0 million was used in
the first quarter of 1997 to buy back warrants to purchase common stock from
PaineWebber R&D Partners II, L.P.

The Company began building additions to its Salt Lake City facility in the
second quarter of 1997 and completion is expected by the first quarter of 1998.
Total expenditures for this project are estimated at $3.0 million. This building
expansion is for increased manufacturing capacity.

OEC believes that it has sufficient liquidity and anticipated cash flow to meet
its obligations in 1997. In addition, OEC continues to carry an unused $10
million line of credit.

Risk Factors

The Company's business involves risks and uncertainties that could cause actual
results to differ materially from those projected. Such risks and uncertainties
include: Product demand and market acceptance; the effect of general economic
conditions and foreign currency fluctuations; the impact of competitive products
and pricing; new product development and commercialization; the effect of the
continuing shift in growth from domestic to international healthcare customers,
and the impact of managed care initiatives in the United States and the ability
to increase operating margins on higher sales.

Future operating results are dependent on the Company's' ability to develop,
manufacture and market innovative products that meet customers' needs. Inherent
in this process are a number of risks that the Company must successfully manage
in order to achieve favorable operating results. The process of developing new
high technology medical products is complex and uncertain and requires
innovative designs that anticipate customer needs, technological trends and
healthcare shifts. There can be no assurance that the Company will be able to
develop and market new products on a cost-effective and timely basis, that such
products will compete favorably with products developed by others or that
technology will not be superseded by new discoveries or breakthroughs. For
example, the delay in introduction of the Series 9600 in 1994 negatively
impacted revenue and earnings for the year.

Because of the substantial length of time and expense associated with bringing
new products through development and regulatory approval to the marketplace, the
medical device industry places considerable importance on obtaining patent,
trademark, copyright and trade secret protection for new technologies, products
and processes. A loss of protection could have a material adverse effect on the
Company's business.

Major items that OEC currently purchases from others include video monitors,
X-ray tubes, image intensifiers, CCD cameras and power supplies. Some of these
parts and components are available from a limited number of single-source
manufacturers or suppliers. While the Company believes any of these
single-source items could be replaced over time, abrupt disruption in the supply
of a part for a product could have a material adverse effect on the Company's
production in cases where the existing inventory of the components is not
adequate to meet the Company's demand for the component during such disruption
and could have a material adverse effect on its financial condition and results
of operations.

The testing, marketing and sale of human healthcare products entails an inherent
risk of product liability, and there can be no assurance that product liability
claims will not be asserted against OEC. Although OEC has product liability
insurance coverage, there can be no assurance that such coverage will provide
adequate coverage against all potential claims.


                                                                               8
<PAGE>   9
As a manufacturer of medical devices, OEC is subject to extensive and rigorous
governmental regulation, principally by the FDA and corresponding state and
foreign agencies. Failure to comply with FDA regulations could result in
sanctions being imposed, including restrictions on the marketing of or recall of
the affected products.

OEC's facilities and manufacturing processes have been periodically inspected by
the FDA and other agencies, but remain subject to audit from time to time. OEC
continues to devote substantial human and financial resources to regulatory
compliance and believes that it remains in substantial compliance with all
applicable federal and state regulations. Nevertheless, there can be no
assurance that the FDA or a state agency will agree with OEC's positions, or
that its GMP compliance will not be challenged at some subsequent point in time.
OEC has received approval from the FDA and foreign regulatory authorities in the
past, when required, to market its products. In general, the length of time for
all reviews and approvals, most particularly from the FDA, has been lengthening
and the review or approval process for medical devices has become substantially
more difficult and expensive. Moreover, regulatory approvals, when granted, may
contain significant limitations on the standards due to unforeseen problems. To
date, product reviews for medical imaging technologies have been obtained within
three to twelve months. There can be no assurance that OEC will be able to
obtain necessary regulatory approvals in the future, and delays in the receipt
of or failure to receive such approvals, the loss of existing approvals or
failure to comply with regulatory requirements could have a material adverse
effect on the business, financial condition and results of operation of OEC.

A portion of the Company's research and development activities, its corporate
headquarters and other critical business operations are located near a major
earthquake fault. The ultimate impact on the Company, significant suppliers and
the general infrastructure is unknown, but operating results could be materially
affected in the event of a major earthquake.

Although OEC believes that it has the product offerings and resources needed for
continuing success, future revenue and margin trends cannot be reliably
predicted and may cause the Company to adjust its operations. Factors external
to the Company can result in volatility of the Company's common stock price.

PART II. Other information.

ITEM 1. Legal proceedings

There are no significant changes in legal proceedings from the previous stated
position in the Company's annual report for 1996 on Form 10K filed with the
Securities & Exchange Commission on March 27, 1997.


                                                                               9
<PAGE>   10
ITEM 6. Exhibits & Reports on Form 8-K

(a) Exhibits:

       Exhibit
       Number                        Description


        3.1     Certificate of Incorporation, as amended. Incorporated by
                reference to the OEC Medical Systems, Inc. Form 10-K, filed
                March 30, 1994.

        3.2     By-Laws, as amended May 15, 1997 and filed herein.

        4       Rights Agreement, dated as of June 20, 1988, between Diasonics,
                Inc. and Bank of America NT&SA. Incorporated by reference to
                Exhibit 4.3 of the Diasonics, Inc. Form 8-K, filed August 1,
                1988.

        10.1    Diasonics, Inc. 1979 Stock Option Plan, amended and restated as
                of June 1, 1982. Incorporated by reference to Exhibit 10.6 of
                the Diasonics, Inc. Registration Statement on Form S-8, filed
                May 2, 1983.

        10.4    Diasonics, Inc. 1990 Stock Option/Stock Purchase Plan.
                Incorporated by reference to Exhibit 10.79 of the Diasonics,
                Inc. Form S-8, filed on May 1, 1991.

        10.5    Warrant for the Purchase of Common Shares issued to PaineWebber
                R&D Partners II, L.P., as amended. Incorporated by reference to
                the OEC Medical Systems, Inc. Form 10-K, filed on March 30,
                1994.

        10.14   Form of Option Agreement used in connection with options having
                service vesting provisions. Incorporated by reference to the OEC
                Medical Systems, Inc. Form 10-K, filed March 30, 1994.

        10.15   Form of Option Agreement used in connection with options having
                milestone provisions. Incorporated by reference to the OEC
                Medical Systems, Inc. Form 10-K, filed March 30, 1994.

        10.16   Form of Option Agreement used in connection with automatic
                option grant program for non-employee directors. Incorporated by
                reference to the OEC Medical Systems, Inc. Form 10-K, filed
                March 30, 1994.

        10.19   Note and Stock Pledge Agreement between Ruediger Naumann-Etienne
                and OEC Medical Systems, Inc., dated September 5, 1995.
                Incorporated by reference to the OEC Medical Systems, Inc. Form
                10-K, filed April 1, 1996.

        10.20   Form of Warrant Agreement used in connection with grant to
                independent contractors for the purchase of common shares.
                Incorporated by reference to the OEC Medical Systems, Inc. Form
                10-K, filed March 27, 1997.

        10.21   Agreement, dated December 17, 1996, to acquire full ownership of
                Barwig Medizinische Systeme GmbH (BMS). Incorporated by
                reference to the OEC Medical Systems, Inc. Form 10-K, filed
                March 27, 1997.

        10.22   Agreement dated January 10, 1997 to repurchase warrants for the
                purchase of common shares issued to PaineWebber R&D Partners II,
                L.P.. Incorporated by reference to the OEC Medical Systems, Inc.
                Form 10-Q, filed May 13, 1997.


                                                                              10
<PAGE>   11
        10.23   Offer of Employment between Joseph W. Pepper and OEC Medical
                Systems, Inc. dated April 21, 1997 and filed herein.

        21      List of Subsidiaries, filed May 13, 1997.

        27      Financial Data Schedule (FDS) for Edgar Filing.

        (b)     Reports on Form 8-K:

                Not applicable


                                                                              11
<PAGE>   12
                                   SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.



OEC MEDICAL SYSTEMS, INC.
(Registrant)





By:   /s/ Randy W. Zundel
      ---------------------------------------
      Randy W. Zundel
      Chief Financial Officer
      (Principal Accounting Officer)


Date: July 30, 1997










                                                                              12
<PAGE>   13


                                 Exhibit Index


       Exhibit
       Number                     Description


        3.1     Certificate of Incorporation, as amended. Incorporated by
                reference to the OEC Medical Systems, Inc. Form 10-K, filed
                March 30, 1994.

        3.2     By-Laws, as amended May 15, 1997 and filed herein.

        4       Rights Agreement, dated as of June 20, 1988, between Diasonics,
                Inc. and Bank of America NT&SA. Incorporated by reference to
                Exhibit 4.3 of the Diasonics, Inc. Form 8-K, filed August 1,
                1988.

        10.1    Diasonics, Inc. 1979 Stock Option Plan, amended and restated as
                of June 1, 1982. Incorporated by reference to Exhibit 10.6 of
                the Diasonics, Inc. Registration Statement on Form S-8, filed
                May 2, 1983.

        10.4    Diasonics, Inc. 1990 Stock Option/Stock Purchase Plan.
                Incorporated by reference to Exhibit 10.79 of the Diasonics,
                Inc. Form S-8, filed on May 1, 1991.

        10.5    Warrant for the Purchase of Common Shares issued to PaineWebber
                R&D Partners II, L.P., as amended. Incorporated by reference to
                the OEC Medical Systems, Inc. Form 10-K, filed on March 30,
                1994.

        10.14   Form of Option Agreement used in connection with options having
                service vesting provisions. Incorporated by reference to the OEC
                Medical Systems, Inc. Form 10-K, filed March 30, 1994.

        10.15   Form of Option Agreement used in connection with options having
                milestone provisions. Incorporated by reference to the OEC
                Medical Systems, Inc. Form 10-K, filed March 30, 1994.

        10.16   Form of Option Agreement used in connection with automatic
                option grant program for non-employee directors. Incorporated by
                reference to the OEC Medical Systems, Inc. Form 10-K, filed
                March 30, 1994.

        10.19   Note and Stock Pledge Agreement between Ruediger Naumann-Etienne
                and OEC Medical Systems, Inc., dated September 5, 1995.
                Incorporated by reference to the OEC Medical Systems, Inc. Form
                10-K, filed April 1, 1996.

        10.20   Form of Warrant Agreement used in connection with grant to
                independent contractors for the purchase of common shares.
                Incorporated by reference to the OEC Medical Systems, Inc. Form
                10-K, filed March 27, 1997.

        10.21   Agreement, dated December 17, 1996, to acquire full ownership of
                Barwig Medizinische Systeme GmbH (BMS). Incorporated by
                reference to the OEC Medical Systems, Inc. Form 10-K, filed
                March 27, 1997.

        10.22   Agreement dated January 10, 1997 to repurchase warrants for the
                purchase of common shares issued to PaineWebber R&D Partners II,
                L.P.. Incorporated by reference to the OEC Medical Systems, Inc.
                Form 10-Q, filed May 13, 1997.

        27      Financial Data Schedule (FDS) for Edgar Filing.